Cancer name Hepatoma
Cancer Type LIHC
Immunotherapy type Oncolytic viruses
Treatment Ad–ABP-PEG-HCBP1
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature VEGF
Official Symbol VEGFA
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description However, oAd–ABP-PEG-HCBP1 treated cells showed significantly suppression of Met or VEGF expression in hepatoma cancer compared with oAd–ABP treated group, but no significant suppression of Met or VEGFexpression was observed in HT1080 cancer cells. Among all experimen-tal groups, the most noticeable suppression of Met or VEGF expressionby oAd–ABP-PEG-HCBP1 complex was investigated with 2.2- for Metor 2.7-fold for VEGF decreased than oAd in Huh7 cells. These resultsdemonstrate that oAd complexed with ABP-PEG-HCBP1 can suppressboth Met and VEGF expression in hepatoma cancer, maximizedtherapeutic value.
PMID 26437261
Title Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.